J0217 — Injection, velmanase alfa-tycv, 1 mg
J0217 is a HCPCS Level II code for injection, velmanase alfa-tycv, 1 mg. It belongs to the Drugs Administered Other Than Oral Method section. Whether Medicare pays it depends on the coverage rule below.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
Physician fee schedule statusE
Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).
Global period: XXX
Want the dollar amount for your locality? The fee calculator applies your GPCI and the current conversion factor.
Medically Unlikely Edits — units per day
The most units of J0217 Medicare will pay on one date of service. Bill more on a single line and it is denied. The limit is not the same in every setting, so the row that matters is the one matching the claim you are building.
- practitioner
- 150 units MAI 3 — Date of Service Edit: Clinical · Prescribing Information
- outpatient
- 150 units MAI 3 — Date of Service Edit: Clinical · Prescribing Information
- DME supplier
- 0 — never payable MAI 3 — Date of Service Edit: Clinical · CMS Policy
The adjudication indicator decides whether exceeding the limit is worth appealing at all: MAI 1 is a line edit you can support with documentation, MAI 3 is a date-of-service edit that is also appealable, and MAI 2 is absolute — no documentation overrides it. CMS MUE 2026Q3.
The CMS record for J0217
- Long descriptor
- Injection, velmanase alfa-tycv, 1 mg
- Short descriptor
- Inj velmanase alfa-tycv 1 mg
- Added
- January 1, 2024
- BETOS
- O1E
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to J0217
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If J0217 is not quite right, the correct code is very often within a few positions of it.
- J0206Injection, allopurinol sodium, 1 mg
- J0207Injection, amifostine, 500 mg
- J0208Injection, sodium thiosulfate (pedmark), 100 mg
- J0209Injection, sodium thiosulfate (hope), 100 mg
- J0210Injection, methyldopate hcl, up to 250 mg
- J0211Injection, sodium nitrite 3 mg and sodium thiosulfate 125 mg (nithiodote)
- J0215Injection, alefacept, 0.5 mgterminated
- J0216Injection, alfentanil hydrochloride, 500 micrograms
- J0218Injection, olipudase alfa-rpcp, 1 mg
- J0219Injection, avalglucosidase alfa-ngpt, 4 mg
- J0220Injection, alglucosidase alfa, 10 mg, not otherwise specified
- J0221Injection, alglucosidase alfa, (lumizyme), 10 mg
- J0222Injection, patisiran, 0.1 mg
- J0223Injection, givosiran, 0.5 mg
- J0224Injection, lumasiran, 0.5 mg
- J0225Injection, vutrisiran, 1 mg
Questions about J0217
What is HCPCS code J0217?
J0217 is a HCPCS Level II code for injection, velmanase alfa-tycv, 1 mg. It sits in the Drugs Administered Other Than Oral Method section.
Does Medicare cover J0217?
The CMS HCPCS file marks J0217 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
How is J0217 paid under the physician fee schedule?
J0217 carries PFS status code E. Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).